It has been proposed that the excess of the familiar risk associated with breast cancer could be explaining by multiple weakly predisposing alleles. Hence there is much interest in the search for low-penetrance genes/variants for breast cancer, which exist with high prevalence in the general population. Maeda and colleagues \[[@B1]\] recently identified the transcriptional repressor FBI1, which they called Pokemon (POK erythroid myeloid ontogenic factor), as a critical factor in oncogenesis. This protein is codified by the *ZBTB7*gene (\'zing finger and BTB domain containing 7\'; GeneID, 51341). Mouse embyronic fibroblasts lacking *Zbtb7*were completely refractory to oncogene-mediated cellular transformation. Conversely, FBI1 overexpression led to overt oncogenic transformation both *in vitro*and *in vivo*in transgenic mice. FBI1 can specifically repress the transcription of the tumor suppressor gene ARF (600160). Maeda and colleagues \[[@B1]\] found that FBI1 is aberrantly overexpressed in human cancers, and its expression levels predict biologic behavior and clinical outcome. On the other hand, tissue microarray analysis (TMA) in breast carcinomas has revealed high levels of Pokemon expression in a subset of these tumors. In addition, the genomic region where the *ZBTB7*gene resides (19p13.3) is a hotspot for chromosomal translocations \[[@B2]\]. *ZBTB7*is therefore a good candidate for a breast cancer low-penetrance gene. We aim to determine whether common polymorphisms (frequency ≥ 10%) in the *ZBTB7*gene are associated with breast cancer risk in Spanish patients. A set of 22 validated binary SNP polymorphisms were selected from public databases (e.g. HapMap) and private databases (e.g. Celera and RealSNP) according to criteria of coverage (average 1 SNP/1.7 kb). These SNPs cover the flanking regions (10,000 bp), including the promoter region, introns, and coding non-synonymous SNPs. About 550 cases and 550 controls have been genotyped. Genotyping was performed using the MassARRAY SNP genotyping system (Sequenom Inc., San Diego, CA, USA).

To our knowledge, this is the first time that the *ZBTB7*gene has been analyzed in breast cancer patients. The results will be presented at the time of the congress and will be interpreted in the light of the worldwide population study shown in another presentation from the same authors.
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